Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $40.8 million.

  • Conmed's Cash & Equivalents rose 6687.93% to $40.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $40.8 million, marking a year-over-year increase of 6687.93%. This contributed to the annual value of $40.8 million for FY2025, which is 6687.93% up from last year.
  • Conmed's Cash & Equivalents amounted to $40.8 million in Q4 2025, which was up 6687.93% from $38.9 million recorded in Q3 2025.
  • Conmed's Cash & Equivalents' 5-year high stood at $53.2 million during Q2 2022, with a 5-year trough of $20.8 million in Q4 2021.
  • For the 5-year period, Conmed's Cash & Equivalents averaged around $33.0 million, with its median value being $32.4 million (2021).
  • Per our database at Business Quant, Conmed's Cash & Equivalents plummeted by 4760.69% in 2023 and then skyrocketed by 6687.93% in 2025.
  • Over the past 5 years, Conmed's Cash & Equivalents (Quarter) stood at $20.8 million in 2021, then soared by 38.83% to $28.9 million in 2022, then decreased by 16.05% to $24.3 million in 2023, then rose by 0.67% to $24.5 million in 2024, then skyrocketed by 66.88% to $40.8 million in 2025.
  • Its Cash & Equivalents was $40.8 million in Q4 2025, compared to $38.9 million in Q3 2025 and $33.9 million in Q2 2025.